B Choufi
Overview
Explore the profile of B Choufi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hunault-Berger M, Maillard N, Himberlin C, Recher C, Schmidt-Tanguy A, Choufi B, et al.
Blood Cancer J
. 2017 Jun;
7(6):e568.
PMID: 28574488
No abstract available.
2.
Hermet E, Cabrespine A, Guieze R, Garnier A, Tempescul A, Lenain P, et al.
J Geriatr Oncol
. 2015 Jun;
6(5):346-52.
PMID: 26116168
Introduction: Limited data is available on the feasibility of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (AHSCT) in elderly patients over 70 years of age with non-Hodgkin's lymphoma...
3.
Choufi B, Thiant S, Trauet J, Cliquennois M, Cherrel M, Boulanger F, et al.
Pathol Biol (Paris)
. 2014 Jun;
62(3):123-8.
PMID: 24906571
In a previous prospective study on 62 patients who underwent an HLA-matched allogeneic stem cell transplantation, we have observed that proportion of donor-derived CCR7(+)/CD4(+) T cells in the graft provided...
4.
Choufi B, Trauet J, Thiant S, Labalette M, Yakoub-Agha I
Bone Marrow Transplant
. 2014 Feb;
49(5):611-5.
PMID: 24566708
In previous studies, we observed that a high proportion of donor-derived CD4(+) T cells expressing the chemokine receptor 7 (CCR7) was a major determinant of acute GVHD, without interfering with...
5.
Kelaidi C, Park S, Sapena R, Beyne-Rauzy O, Coiteux V, Vey N, et al.
Leukemia
. 2013 Feb;
27(6):1283-90.
PMID: 23370672
A large proportion of lower-risk myelodysplastic syndromes (MDS) respond to erythropoiesis-stimulating agents (ESA), but most responses are transient. We updated a previously reported cohort of lower-risk MDS patients treated with...
6.
Kelaidi C, Beyne-Rauzy O, Braun T, Sapena R, Cougoul P, Ades L, et al.
Ann Hematol
. 2013 Jan;
92(5):621-31.
PMID: 23358617
Darbepoetin (DAR), with or without granulocyte colony-stimulating factor (G-CSF), has proved effective in treating anemia in patients with lower-risk myelodysplastic syndrome (MDS), but its effects on quality of life (QoL)...
7.
Michy T, Choufi B, Le Bouedec G, Dauplat J
Gynecol Obstet Fertil
. 2006 Jul;
34(7-8):622-4.
PMID: 16854610
Leiomyoma of the uterus is a frequent benign tumor of non menopausal women. Among possible complications, polycythemia is rare and often unrecognised. We report a very demonstrative case, that of...
8.
Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, et al.
Leukemia
. 2006 Jan;
20(3):400-3.
PMID: 16437142
Imatinib combined with high-dose chemotherapy is now becoming the gold standard for treatment of Philadelphia chromosome-positive acute leukemias. However, in all studies imatinib dosage was tapered to 400-600 mg per...
9.
Mohty M, Jacot W, Faucher C, Bay J, Zandotti C, Collet L, et al.
Leukemia
. 2003 Aug;
17(11):2168-77.
PMID: 12931226
In the setting of reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (allo-SCT), the epidemiology of transplant-related infections is still poorly defined. In 101 high-risk patients who received an...
10.
Bay J, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, et al.
Bone Marrow Transplant
. 2002 Jul;
30(2):95-102.
PMID: 12132048
Allogeneic hematopoietic stem cell transplantation is often used to treat hematologic malignancies. The efficacy of this procedure is due to both myeloablative conditioning and graft-versus-leukemia (GVL). However, the disadvantages of...